dm+d
Unassigned
New Medicines
Chronic graft versus host disease (GvHD)
Information
New molecular entity
Incyte
Incyte
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Category
Janus-associated kinase 1 (JAK1) inhibitor
The number of allogeneic bone marrow and stem cell transplants is increasing worldwide. Graft-versus-host disease (GvHD) is a serious complication of this type of transplant. The incidence of acute GvHD varies widely, ranging from 10-80% depending on risk factors [1].
Chronic graft versus host disease (GvHD)
Oral